SEBI Reg. Investment Advisor

Download App

Help Center Pricing

Recent:

Dr Reddy’s Lab FY12 consolidated net profit rises by 29%

Dr. Reddys Laboratories Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 500124 | NSE: DRREDDY

11 May 2012 Evaluate

Dr Reddy’s Laboratories has reported quarter and year ended March 31, 2012.

The Company has registered growth of 27.68% in fourth quarter ended March 31, 2012 net profit at Rs 211.79 crore as compared to Rs 165.87 crore for the quarter ended March 31, 2011. Total Income has increased by 49.09% to Rs 2051.18 crore January-March quarter, 2012 from Rs 1375.77 crore for the similar quarter a period ago.

The Company, for the full year ended March 31, 2012, posted marginal growth of 2.13% in its net profit of Rs 912.36 crore as compared to Rs 893.31 crore for the year ended March 31, 2011. Company’s total income stood increased by 25.76% to Rs 6821.48 crore for the fiscal year ended March 2012 from Rs 5424.01 crore in the previous fiscal.

On Consolidated basis, the Group’s net profit stood at Rs 342.70 crore for the quarter under review as compared to Rs 334.47 crore for March quarter of previous fiscal, increase of mere 2.46%. Its total income has increased by 34.20% to Rs 2638.65 crore for the quarter as compared to Rs 1966.10 crore for the fourth quarter of FY11.

The Group’s full year ended March 31, 2012 net profit stood at Rs 1426.21 crore for the year ended March 31, 2012 as compared to Rs 1104.00 crore for the year ended March 31, 2011, up by 29.18%. Its total income rose by 30.44% to Rs 9597.24 crore for the year from Rs 7357.77 crore for the previous year.

Dr Reddy’s Laboratories’ board of directors at its meeting held on May 11, 2012, have recommended a final dividend of Rs 13.75 (275%) per equity share of Rs 5 face value, for the financial year 2011-12. The dividend on equity shares, if declared by the shareholders at the ensuing Annual General Meeting, will be credited / dispatched on or after July 27, 2012.

Dr. Reddys Lab Share Price

1209.85 -10.90 (-0.89%)

22-Apr-2026 09:35 View Price Chart

Peers

Company Name	CMP
Sun Pharma Inds.	1660.20
Dr. Reddys Lab	1209.85
Cipla	1224.00
Zydus Lifesciences	924.65
Lupin	2288.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

PROPRIETARY FRAMEWORK

Portfolio
Architecture >
Stock Picking.

Stop managing a collection of "tips." Access the ABC Framework to build a portfolio that survives cycles and compounds wealth.

Core for Stability

Booster for Alpha

Amplifier for Exponential Wealth

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Access Sapphire ABC Strategy →

Limited Capacity for New Fiduciary Partners

Dr Reddy’s Lab FY12 consolidated net profit rises by 29%

MoneyWorks4Me Premium

Follow us at

MoneyWorks4Me

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.